全文获取类型
收费全文 | 38630篇 |
免费 | 2615篇 |
国内免费 | 138篇 |
专业分类
耳鼻咽喉 | 412篇 |
儿科学 | 858篇 |
妇产科学 | 758篇 |
基础医学 | 4611篇 |
口腔科学 | 988篇 |
临床医学 | 4033篇 |
内科学 | 8085篇 |
皮肤病学 | 408篇 |
神经病学 | 3257篇 |
特种医学 | 1294篇 |
外国民族医学 | 1篇 |
外科学 | 6678篇 |
综合类 | 539篇 |
一般理论 | 26篇 |
预防医学 | 3130篇 |
眼科学 | 1195篇 |
药学 | 2455篇 |
中国医学 | 39篇 |
肿瘤学 | 2616篇 |
出版年
2023年 | 157篇 |
2022年 | 248篇 |
2021年 | 712篇 |
2020年 | 437篇 |
2019年 | 634篇 |
2018年 | 770篇 |
2017年 | 554篇 |
2016年 | 651篇 |
2015年 | 767篇 |
2014年 | 1117篇 |
2013年 | 1710篇 |
2012年 | 2453篇 |
2011年 | 2549篇 |
2010年 | 1447篇 |
2009年 | 1355篇 |
2008年 | 2325篇 |
2007年 | 2393篇 |
2006年 | 2394篇 |
2005年 | 2578篇 |
2004年 | 2488篇 |
2003年 | 2278篇 |
2002年 | 2166篇 |
2001年 | 281篇 |
2000年 | 221篇 |
1999年 | 367篇 |
1998年 | 511篇 |
1997年 | 412篇 |
1996年 | 348篇 |
1995年 | 343篇 |
1994年 | 279篇 |
1993年 | 264篇 |
1992年 | 217篇 |
1991年 | 192篇 |
1990年 | 159篇 |
1989年 | 155篇 |
1988年 | 148篇 |
1987年 | 160篇 |
1986年 | 148篇 |
1985年 | 178篇 |
1984年 | 264篇 |
1983年 | 259篇 |
1982年 | 370篇 |
1981年 | 332篇 |
1980年 | 308篇 |
1979年 | 153篇 |
1978年 | 194篇 |
1977年 | 201篇 |
1976年 | 191篇 |
1975年 | 149篇 |
1973年 | 149篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
Dan Weng Robyn Marty-Roix Sandhya Ganesan Megan K. Proulx Gregory I. Vladimer William J. Kaiser Edward S. Mocarski Kimberly Pouliot Francis Ka-Ming Chan Michelle A. Kelliher Phillip A. Harris John Bertin Peter J. Gough Dmitry M. Shayakhmetov Jon D. Goguen Katherine A. Fitzgerald Neal Silverman Egil Lien 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(20):7391-7396
992.
Chiara Gorrini Bevan P. Gang Christian Bassi Andrew Wakeham Shakiba Pegah Baniasadi Zhenyue Hao Wanda Y. Li David W. Cescon Yen-Ting Li Sam Molyneux Nadia Penrod Mathieu Lupien Edward E. Schmidt Vuk Stambolic Mona L. Gauthier Tak W. Mak 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(12):4472-4477
993.
Ethan A. Winkler Jesse D. Sengillo Abhay P. Sagare Zhen Zhao Qingyi Ma Edward Zuniga Yaoming Wang Zhihui Zhong John S. Sullivan John H. Griffin Don W. Cleveland Berislav V. Zlokovic 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(11):E1035-E1042
Humans with ALS and transgenic rodents expressing ALS-associated superoxide dismutase (SOD1) mutations develop spontaneous blood–spinal cord barrier (BSCB) breakdown, causing microvascular spinal-cord lesions. The role of BSCB breakdown in ALS disease pathogenesis in humans and mice remains, however, unclear, although chronic blood–brain barrier opening has been shown to facilitate accumulation of toxic blood-derived products in the central nervous system, resulting in secondary neurodegenerative changes. By repairing the BSCB and/or removing the BSCB-derived injurious stimuli, we now identify that accumulation of blood-derived neurotoxic hemoglobin and iron in the spinal cord leads to early motor-neuron degeneration in SOD1G93A mice at least in part through iron-dependent oxidant stress. Using spontaneous or warfarin-accelerated microvascular lesions, motor-neuron dysfunction and injury were found to be proportional to the degree of BSCB disruption at early disease stages in SOD1G93A mice. Early treatment with an activated protein C analog restored BSCB integrity that developed from spontaneous or warfarin-accelerated microvascular lesions in SOD1G93A mice and eliminated neurotoxic hemoglobin and iron deposits. Restoration of BSCB integrity delayed onset of motor-neuron impairment and degeneration. Early chelation of blood-derived iron and antioxidant treatment mitigated early motor-neuronal injury. Our data suggest that BSCB breakdown contributes to early motor-neuron degeneration in ALS mice and that restoring BSCB integrity during an early disease phase retards the disease process.The blood–brain barrier (BBB) and blood–spinal cord barrier (BSCB) prevent entry of toxic circulating molecules and cells into the central nervous system (CNS) (1). Amyotrophic lateral sclerosis (ALS) is the most prominent adult motor-neuron disorder resulting in progressive motor-neuron loss in the spinal cord, brainstem, and motor cortex (2). Most ALS cases are sporadic (90%) whereas 10% are familial ALS. Over twenty independent studies in postmortem human tissue and cerebrospinal fluid (CSF) sampling from living ALS patients have established that the BBB and BSCB are damaged in familial and sporadic ALS, as reviewed elsewhere (1, 3). This BBB and BSCB disruption has been shown by spinal-cord and/or motor-cortex accumulation of different plasma proteins (e.g., IgG, fibrin, thrombin), erythrocytes, erythrocyte-derived hemoglobin and iron-containing hemosiderin, elevated CSF/serum albumin ratios, and diminished expression or degradation of the BSCB tight-junction proteins (1, 3–5). Deposition of hemoglobin-derived iron within the CNS has also been shown in ALS patients (3, 6, 7). Because human postmortem studies reflect, however, end-stage disease, it has remained unclear as to which stage of disease is enhanced by BSCB disruption. Longitudinal CSF or BSCB imaging studies have yet to be performed in living ALS patients (3) to clarify whether spinal-cord vascular dysfunction contributes to early- or late-stage disease.Transgenic rodents expressing human ALS-associated Cu/Zn superoxide dismutase (SOD1) mutations that represent 20% of all familial cases also develop a spontaneous BBB/BSCB disruption (8–12) similar to vascular pathology reported in humans (1, 3–7). Mice with a chronic BBB disruption due to aberrant signal transduction between the central nervous system endothelial cells and pericytes or astrocytes and pericytes develop a chronic BBB opening accompanied by accumulation of toxic blood-derived products in the central nervous system and secondary functional and structural neuronal changes (13–15).To determine whether BSCB disruption contributes to fatal paralytic disease caused by expression of an ALS-causing mutant, we now report how perturbing the BSCB, repairing the BSCB, and/or removing the BSCB-derived injurious stimuli influence development of disease in SOD1G93A mice that develop a spontaneous BSCB breakdown (8, 9, 12). 相似文献
994.
Shih-Chieh Shao MS Kai-Cheng Chang MS Rong-Nan Chien MD Swu-Jane Lin PhD Ming-Jui Hung MD Yuk-Ying Chan MS Yea-Huei Kao Yang BPharm Edward Chia-Cheng Lai PhD 《Diabetes, obesity & metabolism》2020,22(1):128-134
Clinical trials have indicated that sodium-glucose co-transporter-2 (SGLT2) inhibitors have a favourable effect on serum alanine aminotransferase (ALT) levels in people with type 2 diabetes (T2D), but supporting evidence from real-world studies is lacking. We identified patients with T2D who initiated SGLT2 inhibitors during the period 2016 to 2017 from Chang Gung Research Database, which covers 1.3 million individuals from seven hospitals (6% of the Taiwan population). We classified patients by baseline ALT level and evaluated changes in ALT values from baseline to 1 year after initiation of SGLT2 inhibitors. We identified 11 690 new users of SGLT2 inhibitors with a mean (SD) age of 59.3 (11.8) years. The mean (SD) glycated haemoglobin and ALT levels were 8.9 (1.7)% and 34.7 (28.9) U/L at baseline, respectively. The mean change in ALT levels was −5.0 U/L (95% confidence interval [CI] –6.4, −3.5) 1 year after initiation of SGLT2 inhibitors. In patients with ALT levels ≤1× the upper limit of normal (ULN), the change in ALT levels was 1.6 U/L (95% CI –0.1, 3.4), while in those with ALT levels >1× ULN, the change in ALT levels was −26.5 U/L (95% CI –28.6, −24.3). The higher the baseline ALT level, the greater the decline after SGLT2 inhibitor treatment. Our findings suggest the initiation of SGLT2 inhibitors for T2D management could improve serum ALT levels in clinical practice, particularly in patients with especially high ALT levels. 相似文献
995.
Assessment of ischaemia and interventions to improve perfusion are key elements in the management of the diabetic foot ulcer to achieve wound healing. This article will review, analyse and interpret the value of clinical information in determining the likelihood of limb ischaemia and thereby the need for referral to a vascular specialist. I conducted an historical review of the genesis of several currently recommended clinical signs and their diagnostic properties in the assessment of limb ischaemia. Changes in limb ischaemia probability based on such results were calculated using Bayes theorem, and the use of such probabilities is discussed in the context of the threshold approach to clinical decision making. Some clinical signs have negligible value in altering probability of limb ischaemia, possibly because they were advocated by Buerger for the diagnosis of thromboangiitis obliterans, an occlusive vascular disease of a different pathophysiology than atherosclerosis. Pedal pulse palpation, the most widely studied clinical sign, will marginally change a pre‐test probability of ischaemia of 50% to 76% if positive (abnormal pulses) and to 36% if negative (normal pulses). Higher or lower pre‐test probabilities of ischaemia will change the post‐test probabilities such that these are too low or high to rule in or rule out ischaemia, respectively. Individual clinical signs convey little information regarding the presence of limb ischaemia but may have some value in combination or with pre‐test probability near 50% in the assessment of ischaemia and the decision to refer for a vascular consultation. 相似文献
996.
Rachael O. Forsythe Jan Apelqvist Edward J. Boyko Robert Fitridge Joon Pio Hong Konstantinos Katsanos Joseph L. Mills Sigrid Nikol Jim Reekers Maarit Venermo R. Eugene Zierler Nicolaas C. Schaper Robert J. Hinchliffe 《Diabetes/metabolism research and reviews》2020,36(Z1)
The accurate identification of peripheral artery disease (PAD) in patients with diabetes and foot ulceration is important, in order to inform timely management and to plan intervention including revascularisation. A variety of non‐invasive tests are available to diagnose PAD at the bedside, but there is no consensus as to the most useful test, or the accuracy of these bedside investigations when compared to reference imaging tests such as magnetic resonance angiography, computed tomography angiography, digital subtraction angiography or colour duplex ultrasound. Members of the International Working Group of the Diabetic Foot updated our previous systematic review, to include all eligible studies published between 1980 and 2018. Some 15 380 titles were screened, resulting in 15 eligible studies (comprising 1563 patients, of which >80% in each study had diabetes) that evaluated an index bedside test for PAD against a reference imaging test. The primary endpoints were positive likelihood ratio (PLR) and negative likelihood ratio (NLR). We found that the most commonly evaluated test parameter was ankle brachial index (ABI) <0.9, which may be useful to suggest the presence of PAD (PLR 6.5) but an ABI value between 0.9 and 1.3 does not rule out PAD (NLR 0.31). A toe brachial index >0.75 makes the diagnosis of PAD less likely (NLR 0.14‐0.24), whereas pulse oximetry may be used to suggest the presence of PAD (if toe saturation < 2% lower than finger saturation; PLR 17.23‐30) or render PAD less likely (NLR 0.2‐0.27). We found that the presence of triphasic tibial waveforms has the best performance value for excluding a diagnosis of PAD (NLR 0.09‐0.28), but was evaluated in only two studies. In addition, we found that beside clinical examination (including palpation of foot pulses) cannot reliably exclude PAD (NLR 0.75), as evaluated in one study. Overall, the quality of data is generally poor and there is insufficient evidence to recommend one bedside test over another. While there have been six additional publications in the last 4 years that met our inclusion criteria, more robust evidence is required to achieve consensus on the most useful non‐invasive bedside test to diagnose PAD. 相似文献
997.
998.
999.
1000.